Skip to main content
GenSight Biologics S.A. logo

GenSight Biologics S.A. — Investor Relations & Filings

Ticker · SIGHT ISIN · FR0013183985 LEI · 549300NK4AB8OUEX1F54 PA Manufacturing
Open in API
Filings indexed 628 across all filing types
Latest filing 2025-08-28 Report Publication Anno…
Country FR France
Listing PA SIGHT

About GenSight Biologics S.A.

https://www.gensight-biologics.com

GenSight Biologics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative gene therapies for patients with neurodegenerative retinal diseases and disorders of the central nervous system. The company's therapeutic approach is based on two core technology platforms: the Mitochondrial Targeting Sequence (MTS) and optogenetics. Its lead product candidate, LUMEVOQ (lenadogene nolparvovec), is a gene therapy in late-stage clinical development for treating vision loss from rare mitochondrial diseases. The company's pipeline also includes GS030, an optogenetic-based therapy in clinical trials for retinal degenerative diseases.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) regarding the postponement of a scheduled financial report release. It does not contain the financial results themselves, but rather informs the market about a change in the reporting timeline. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) as it concerns the timing and release of a company report.
2025-08-28 English
Inside Information / Operations of the issuer (acquisitions, sales...)
Capital/Financing Update Classification · 98% confidence The document is explicitly titled "PRESS RELEASE" and announces the "Closing of Approximately €500,000 of Additional Financing." It details the issuance of New Shares and Warrants resulting from a 'Reserved Offering' and mentions capital increase procedures under French Commercial Code. This content directly relates to fundraising and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report publication (RPA), but the primary subject matter is the financing event itself.
2025-07-22 English
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces the final settlement ("règlement livraison") of a supplementary financing round ("financement complémentaire") involving the issuance of new shares and warrants (ABSA). This action directly relates to the company's fundraising and capital structure changes. Based on the definitions, the most appropriate category is 'Capital/Financing Update' (CAP). It is not a full 10-K, an Earnings Release (ER), or a simple Report Publication Announcement (RPA), as it details the completion and terms of a specific financing event.
2025-07-22 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from GenSight Biologics announcing the publication of a scientific article in a medical journal regarding clinical trial results for their drug LUMEVOQ. It does not constitute a formal financial report, proxy statement, or regulatory filing, but rather a corporate communication regarding research and development progress. According to the provided definitions, general regulatory announcements and miscellaneous filings that do not fit into specific categories are classified as RNS.
2025-07-17 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release from GenSight Biologics announcing the publication of a scientific study in a medical journal regarding their gene therapy product, LUMEVOQ. It provides details on the study's findings, methodology, and clinical trial context. As it is a general regulatory/corporate announcement that does not fit into specific financial reporting categories like 10-K, IR, or ER, and is not a report publication announcement (RPA) for a financial report, it falls under the general regulatory filing category.
2025-07-17 English
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Share Issue/Capital Change Classification · 100% confidence The document is a press release from GenSight Biologics announcing a capital increase (share issuance) reserved for an existing shareholder. It details the number of shares, subscription price, use of proceeds, and the impact on the company's capital structure and shareholding. This falls under the category of share issuance and capital changes.
2025-07-17 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.